PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2011-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 951
- Registration Number
- NCT00561951
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge
Phase 2
Completed
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT00562120
- Locations
- 🇺🇸
Pfizer Investigational Site, Omaha, Nebraska, United States
Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.
Phase 2
Withdrawn
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: PNU-165442G; [S,S]-reboxetineDrug: Atomoxetine
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00562055
Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments
Phase 2
Completed
- Conditions
- Colorectal Neoplasm
- Interventions
- Biological: CP-751, 871
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2013-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 168
- Registration Number
- NCT00560560
- Locations
- 🇬🇧
Pfizer Investigational Site, Southampton, United Kingdom
Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT00560573
- Locations
- 🇪🇸
Pfizer Investigational Site, Sevilla, Spain
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
Phase 1
Completed
- Conditions
- Ewing's Sarcoma Family of Tumors
- Interventions
- Drug: CP-751,871
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 138
- Registration Number
- NCT00560235
- Locations
- 🇬🇧
Pfizer Investigational Site, Oxford, United Kingdom
A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: PlaceboDrug: PH-797804
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 230
- Registration Number
- NCT00559910
- Locations
- 🇬🇧
Pfizer Investigational Site, Edinburgh, United Kingdom
A Study Of PF-03732010 In Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: PF-03732010
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2012-03-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT00557505
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: PF-03446962
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT00557856
- Locations
- 🇺🇸
Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina, United States
🇮🇹S.C Diagnostica Radiologica 2, Milano, Italy
🇮🇹S.C. Chirurgia Generale Indirizzo Oncologico 1 (epato-gastro-pancreatica), Milano, Italy
A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT00556998
- Locations
- 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath